PetMed Express (PETS) Stock Price, News & Analysis

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetMed Express in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PETS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PETS, but not buy additional shares or sell existing shares.
View PETS analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month target prices for PetMed Express' stock. Their PETS share price targets range from $6.50 to $20.00. On average, they predict the company's share price to reach $13.25 in the next twelve months. This suggests a possible upside of 121.6% from the stock's current price.
View analysts price targets for PETS or view top-rated stocks among Wall Street analysts.

PetMed Express' stock was trading at $7.56 at the start of the year. Since then, PETS stock has decreased by 20.9% and is now trading at $5.98.
View the best growth stocks for 2024 here.

PetMed Express, Inc. (NASDAQ:PETS) posted its quarterly earnings data on Monday, October, 30th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.18 by $0.09. The firm earned $71 million during the quarter, compared to analysts' expectations of $77.13 million. PetMed Express had a negative net margin of 2.25% and a positive trailing twelve-month return on equity of 0.93%. During the same quarter in the prior year, the company earned $0.13 earnings per share.

PetMed Express announced a quarterly dividend on Monday, July 31st. Investors of record on Monday, August 14th will be paid a dividend of $0.30 per share on Friday, August 18th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 20.07%. The ex-dividend date is Friday, August 11th.
Read our dividend analysis for PETS.

ETFs with the largest weight of PetMed Express (NASDAQ:PETS) stock in their portfolio include Formidable ETF (FORH), Amplify Online Retail ETF (IBUY), Global SuperDividend US ETF (DIV) and ProShares Pet Care ETF (PAWZ).Global X E-Commerce ETF (EBIZ).

PetMed Express updated its third quarter 2024 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65.3 million-$65.3 million, compared to the consensus revenue estimate of $68.0 million.

5 employees have rated PetMed Express Chief Executive Officer Mendo Akdag on Glassdoor.com. Mendo Akdag has an approval rating of 46% among the company's employees. This puts Mendo Akdag in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other PetMed Express investors own include Intel (INTC), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Verizon Communications (VZ), Netflix (NFLX) and Micron Technology (MU).

PetMed Express' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.75%), Charles Schwab Investment Management Inc. (2.02%), Profit Investment Management LLC (0.86%), Trexquant Investment LP (0.54%), UBS Group AG (0.33%) and Formidable Asset Management LLC (0.31%). Insiders that own company stock include Bruce S Rosenbloom, Christine Chambers, Gian Fulgoni and Mathew N Hulett.
View institutional ownership trends.

Shares of PETS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.